- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02849327
Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
By enrolling patients with recurrent pharyngeal cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using cryosurgery and natural killer (NK) cells.
The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510665
- Fuda cancer institute of Fuda cancer hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence
- Body tumor 1-6, the maximum tumor length < 5 cm
- KPS ≥ 70, lifespan > 6 months
- Platelet count ≥ 80×109/L,white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L
Exclusion Criteria:
- Patients with cardiac pacemaker
- Patients with brain metastasis
- Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cryosurgery and NK immunotherapy
In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies.
The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
|
Percutaneous ablation under CT or ultrasound guidance
Other Names:
Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
|
Active Comparator: Cryosurgery
In this group, the patients will receive comprehensive cryosurgery to clear all big tumors.
The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
|
Percutaneous ablation under CT or ultrasound guidance
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relief degree of tumors
Time Frame: 3 months
|
It will be evaluated by the Response Evaluation Criteria in Solid Tumors(RECIST)
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progress free survival(PFS)
Time Frame: 1 year
|
1 year
|
Overall survival(OS)
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NK-Pharynx
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Pharyngeal Cancer
-
National University Hospital, SingaporeMerck Sharp & Dohme LLCNot yet recruitingMetastatic Nasopharyngeal Cancer | Locally Recurrent CancerSingapore
-
National Cancer Institute (NCI)CompletedRecurrent Nasopharyngeal Cancer | Stage IV Nasopharyngeal CancerUnited States
-
BeiGeneActive, not recruitingRecurrent or Metastatic Nasopharyngeal CancerChina, Taiwan, Thailand
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent / Metastatic Nasopharyngeal CancerChina
-
Fujian Cancer HospitalCompletedNasopharyngeal Cancer RecurrentChina
-
Royal Marsden NHS Foundation TrustImperial College LondonActive, not recruitingRecurrent Oropharynx CarcinomaUnited Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingCastleman Disease | Lymphangioleiomyomatosis | Digestive System Carcinoma | Malignant Neoplasm | Recurrent Breast Carcinoma | Recurrent Thyroid Gland Carcinoma | Metastatic Urothelial Carcinoma | Malignant Female Reproductive System Neoplasm | Neurofibromatosis Type 2 | Recurrent Adult Soft Tissue Sarcoma and other conditionsUnited States
-
The University of Hong KongMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...Active, not recruitingNasopharyngeal Carcinoma | Metastatic Cancer | Recurrent Carcinoma | Non-keratinizing CarinomaHong Kong
-
National Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage IV Hypopharyngeal... and other conditionsUnited States
-
China Medical University HospitalCompletedHypopharyngeal Cancer | Oral CancerTaiwan
Clinical Trials on Cryosurgery
-
Khon Kaen UniversityTerminatedHuman Papillomavirus Clearance at 12 MonthsThailand
-
Larkin Community HospitalWithdrawn
-
Milton S. Hershey Medical CenterCompletedSeborrheic KeratosisUnited States
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedBreast Cancer RecurrentChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)TerminatedPain | Kidney Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Melanoma (Skin)United States
-
photonamic GmbH & Co. KGCompleted
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedMetastatic Renal Cell CancerChina
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed
-
Fuda Cancer Hospital, GuangzhouJinan University GuangzhouCompleted
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedMetastatic Esophageal CancerChina